Hosted on MSN2h
Travere takes rare disease kidney drug to FDA despite failed trial
Travere’s stock price climbed by 14% following the announcement that it will seek an FDA label expansion for Filspari.
Yahoo Finance5d
Novartis Rises 5% Since Q4 Earnings: How Should You Play the Stock?
and Fabhalta (paroxysmal nocturnal hemoglobinuria) are likely to drive Novartis’ growth in the coming years. Kisqali put up a stellar performance in 2024 as sales grew across all regions ...
The Motley Fool9d
2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond
Cosentyx will soon see its U.S. patent expire, but Novartis does have newer medicines that should help drive top-line growth. These include Fabhalta, a treatment for paroxysmal nocturnal ...
Yahoo Finance6d
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
Leqvio and Fabhalta should fuel growth through 2030 and beyond. NVS boasts a Momentum Style Score of B and VGM Score of A, and holds a Zacks Rank #3 (Hold) rating. Shares of Novartis has seen some ...
Novartis Pharma AG: Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024
Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance ...
Nasdaq6d
Novartis Rises 5% Since Q4 Earnings: How Should You Play the Stock?
Novartis obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals ALNY. New drug Fabhalta for PNH and IgAN ...